Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9724279 | 0.75 | GRM2 (0.47) | EPHX2HSD11B1EPHX1CYP2C9MAPT | |
| SCHEMBL2194681 | 0.75 | EPHX2 (0.39) | EPHX2HSD11B1EPHX1CYP2C9MAPT | |
| SCHEMBL6840624 | 0.69 | EPHX2 (0.46) | EPHX2HSD11B1EPHX1L3MBTL1HSD17B10 | |
| SCHEMBL26364080 | 0.67 | CYP2C9 (0.35) | EPHX2CYP2C9 | |
| Adamantane SCHEMBL28647589 | 0.67 | GRM2 (0.41) | EPHX2HSD11B1EPHX1ALDH1A1TSHR | |
| SCHEMBL6456147 | 0.67 | CYP2C9 (0.41) | EPHX2HSD11B1EPHX1CYP2C9 | |
| SCHEMBL2982997 | 0.67 | CYP2C9 (0.41) | EPHX2HSD11B1CYP2C9 | |
| SCHEMBL2196303 | 0.67 | HSD11B1 (0.38) | EPHX2HSD11B1EPHX1L3MBTL1GRM2 | |
| SCHEMBL4067305 | 0.66 | CYP2C9 (0.38) | EPHX2EPHX1CYP2C9 | |
| SCHEMBL10322394 | 0.66 | EPHX2 (0.35) | EPHX2HSD11B1EPHX1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522868-B2 | Tetrakis(ether-substituted formylphenyl) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160016884-A1 | NEW TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
| US-8043789-B2 | Photosensitive compound and photoresist composition including the same | DONGJIN SEMICHEM CO., LTD. (KR) | 2011-10-25 | — | — | US | disclosed |
| US-20110172457-A1 | TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED FROM THE SAME | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20090155714-A1 | PHOTOSENSITIVE COMPOUND AND PHOTORESIST COMPOSITION INCLUDING THE SAME | DONGJIN SEMICHEM CO., LTD. (KR) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016884-A1 | NEW TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) | AHR, PAH, ALK | EPHX2 1161/4885HSD11B1 699/4885EPHX1 1577/4885 |
| US-20090155714-A1 | PHOTOSENSITIVE COMPOUND AND PHOTORESIST COMPOSITION INCLUDING THE SAME | CRY1, CRY2, PPOX | EPHX2 2550/4885HSD11B1 2364/4885EPHX1 3328/4885 |
| US-20110172457-A1 | TETRAKIS(ETHER-SUBSTITUTED FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED FROM THE SAME | AHR, PAH, ARNT | EPHX2 3217/4885HSD11B1 3313/4885EPHX1 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.